RecruitingPhase 2NCT04205968
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Studying Rare epithelial tumor of small intestine
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Michael J OvermanSWOG Cancer Research Network
- Intervention
- Fluorouracil(drug)
- Enrollment
- 94 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (30)
- Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
- Alaska Women's Cancer Care, Anchorage, Alaska, United States
- Anchorage Oncology Centre, Anchorage, Alaska, United States
- Katmai Oncology Group, Anchorage, Alaska, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Kingman Regional Medical Center, Kingman, Arizona, United States
- Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
- Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
- CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States
- CARTI Cancer Center, Little Rock, Arkansas, United States
- Kaiser Permanente-Anaheim, Anaheim, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04205968 on ClinicalTrials.govOther trials for Rare epithelial tumor of small intestine
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT04729322Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-respondersM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT02949219Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryAcademic and Community Cancer Research United
See all trials for Rare epithelial tumor of small intestine →